ReviewMarine drugs2020
Current Research Landscape of Marine-Derived Anti-Atherosclerotic Substances.
Review in Marine drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Research Progress on Marine Active Substances in Improving Atherosclerosis.Marine drugs · 2026Review
- Marine-Derived Polymers-Polysaccharides as Promising Natural Therapeutics for Atherosclerotic Cardiovascular Disease.Marine drugs · 2025Review
- Review
- Marine Compounds and Age-Related Diseases: The Path from Pre-Clinical Research to Approved Drugs for the Treatment of Cardiovascular Diseases and Diabetes.Marine drugs · 2024Review
- Marine-Derived Compounds Applied in Cardiovascular Diseases: Submerged Medicinal Industry.Marine drugs · 2023Review
- Marine Biological Macromolecules and Chemically Modified Macromolecules; Potential Anticoagulants.Marine drugs · 2022Review
- The Sponge-Derived Brominated Compound Aeroplysinin-1 Impairs the Endothelial Inflammatory Response through Inhibition of the NF-κB Pathway.Marine drugs · 2022Article
- Biotechnological Innovations from Ocean: Transpiring Role of Marine Drugs in Management of Chronic Disorders.Molecules (Basel, Switzerland) · 2022Review
- Recent Progress in Antioxidant Active Substances from Marine Biota.Antioxidants (Basel, Switzerland) · 2022Review
- Article
- Marine Natural Products and Coronary Artery Disease.Frontiers in cardiovascular medicine · 2021Review
- Pharmacokinetics of Marine-Derived Drugs.Marine drugs · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Atherosclerosis is a chronic disease characterized by lipid accumulation and chronic inflammation of the arterial wall, which is the pathological basis for coronary heart disease, cerebrovascular disease and thromboembolic disease. Currently, there is a lack of low-cost therapeutic agents that effectively slow the progression of atherosclerosis. Therefore, the development of new drugs is urgently needed. The research and development of marine-derived drugs have gained increasing interest from researchers across the world. Many marine organisms provide a rich material basis for the development of atherosclerotic drugs. This review focuses on the latest technological advances in the structures and mechanisms of action of marine-derived anti-atherosclerotic substances and the challenges of the application of these substances including marine polysaccharides, proteins and peptides, polyunsaturated fatty acids and small molecule compounds. Here, we describe the theoretical basis of marine biological resources in the treatment of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.